Explore all of our publications and interviews in academic journals and mainstream media using the filter and search functions.
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.
Drug Pricing Lab 10/11/2019
Impact of President's Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.
Drug Pricing Lab 03/08/2019
Overview of Original Subscription Model and Features of LA and WA Proposals
An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.
Drug Pricing Lab 01/29/2019
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
Our response to the Trump administration’s Request for Information on implementing an international pricing index model for Medicare Part B drugs.
Drug Pricing Lab 12/31/2018
DPL responds to HHS Blueprint (May 16, 2018)
The Drug Pricing Lab responds to the Trump Administration’s Request for Information on lowering drug prices with a summary of our findings.
Drug Pricing Lab 07/16/2018
No Results Found